GlobeNewswire

myToys Delivers Oracle e-Business Suite Projects Faster Using Delphix Dynamic Data Platform

Dela

Top European family shopping retailer selects Delphix to reduce time-to-market, improve software quality, offer faster disaster recovery, accelerate financial close and reduce costs

FRANKFURT, Germany and REDWOOD CITY, Calif., Oct.  25, 2017  (GLOBE NEWSWIRE) -- Delphix, the company that has changed the dynamics of managing and consuming data, today announced top online retailer myToys has selected the Delphix Dynamic Data Platform to support their Oracle E-Business Suite (EBS) projects and drive continuous innovation.

myToys uses Oracle EBS to run everything from purchasing, finance and accounting to order/ inventory management, customer service and logistics. By adopting the Delphix Dynamic Data Platform, myToys expects to use secure, up-to-date data to improve application development and testing processes, reduce time-to-market and improve quality.

myToys ERP embraces DevOps in many aspects of the Software Development Life Cycle, the goal of which is to strive for daily application releases that keep up with market changes; however, they found that their test automation processes were broken and inhibited both quality and speed. Before the Delphix implementation, their development team shared two environments between them to support the 70+ projects they worked on per quarter, which inhibited the development process and stifled innovation.

"With Delphix, our vision is to let any developer generate an environment on-demand risk-free with the right data and application stack. Data operators will be able to provide self-service access to developers, accelerating the speed at which they can work on critical projects," stated Ralf Schmilewski, head of ERP Development with myToys.

After evaluating potential solutions, myToys selected Delphix, as the team found the platform to be a proven solution for Oracle EBS projects. Other important factors in the decision were the mature DevOps features in the Delphix Dynamic Data Platform and ease of implementation resulting in rapid time-to-value.

Schmilewski continued, "Delphix has many Oracle EBS customers around the world and demonstrated a wealth of expertise and knowledge in their German team. We felt confident in the best practices and data expertise by the Delphix technical staff. In addition, Delphix self-service features are built for test automation. Delphix is the missing link in DevOps."

With data forecasted to grow at 20% per year, myToys is also expecting a considerable storage savings due to the way Delphix virtualizes at the data level.

"We are delighted that myToys has chosen Delphix and recognizes the value the Delphix Dynamic Data Platform will deliver to their Oracle EBS projects," explained Minas Botzoglou, Regional Sales Manager for DACH at Delphix. "We look forward to helping more companies in Europe and across the world maximize the effectiveness of DevOps investments to drive innovation."

For more information on the Delphix Dynamic Data Platform, please visit:

·        Platform Solution Brief
·        Link to the Cloud Release

About Delphix

Delphix's mission is to free companies from data friction and accelerate innovation. Fortune 100 companies use the Delphix Dynamic Data Platform to connect, virtualize, secure and manage data in the cloud and in on-premise environments. For more information visit www.delphix.com

About the MYTOYS GROUP

The MYTOYS GROUP - with headquarters in Berlin and part of the Otto Group - is one of Germany's most successful E-Commerce companies for the target group of families and women. Since 1999, the MYTOYS GROUP operates under the brand myToys Germany's leading online shop and retailer for toy, leisure product and baby care and 16 retail stores trading under the same name. myToys is the leading Multi-Channel-Provider for children's products in German speaking countries. In 2010, the women's fashion online store ambellis was launched, which also belongs to the MYTOYS GROUP. Since 2013, the online shoe shop mirapodo and the shopping community limango also belong to the MYTOYS GROUP family. With the innovative combined shopping concept, customers are able to purchase simultaneously in the online shops myToys, ambellis and mirapodo. With just one account and a shared shopping cart, the online shopping experience is easy and convenient. The MYTOYS GROUP currently employs more than 2,000 employees. Sales revenue amounted to over 500 million euros in the fiscal year 2015/16.

CONTACT:

Alex Plant / alex.plant@delphix.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Delphix via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum